Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities
Maria Rita Taliani(University of Perugia), Renzo Poggio(Ente Ospedaliero Ospedali Galliera), Paolo Prandoni(University of Padua), Giuliana Guazzaloca(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Cecilia Becattini(University of Perugia), Rosamaria Salvi(University of Trieste), Walter Ageno(University of Padua), Marco Moia(Ospedale Maggiore), Giancarlo Agnelli(University of Perugia), Mario Bazzan(Ospedale San Giovanni Bosco), Mauro Silingardi(Ospedale Maggiore Carlo Alberto Pizzardi), Davide Imberti
Cited by 8
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
|Blood|2002|1.9k
Oral Anticoagulant Therapy
|CHEST Journal|2012|1.5k
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
|Blood Advances|2020|1.4k
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
|Journal of Thrombosis and Haemostasis|2010|1.2k